Target intelligence / Profile preview

Novel transcript, antisense to NOMO3 (ENSG00000297752)

Target
ENSG00000297752
Molecular classification
Long non-coding RNA (lncRNA), Antisense transcript
01

Overview

ENSG00000297752 refers to a novel, uncharacterized long noncoding RNA transcript, antisense to the NOMO3 gene. It is detected in genomic surveys and lncRNA catalogs, but does not encode a protein and does not show established biological function, disease relevance, or druggability. Antisense lncRNAs can theoretically regulate their sense partners via transcriptional interference, RNA-RNA interactions, or epigenetic modification, but no such roles or clinical significance for ENSG00000297752 have been described in the literature or major databases. This entry should not be considered a classical pharmacological, diagnostic, or therapeutic target. If structured information for therapeutic target pipelines is needed, this lncRNA should be flagged as not a conventional therapeutic target and likely out-of-scope for drug development or biomarker use, based on publicly available data as of September 2025.

Other names
Novel transcript, antisense to NOMO3ENSG00000297752
02

Mechanism of action

Not applicable; there are no therapeutics targeting this RNA

03

Biological functions

Unknown; as a noncoding antisense RNA, it may be involved in regulation of NOMO3 expression or local chromatin structure, but no functions have been formally described
04

Disease associations

None established; no disease association is reported in current databases as of September 2025
05

Safety considerations

Not applicable; as there are no known drugs or therapies targeting this transcript, safety concerns are not described
06

Interacting drugs

None reported; no drugs are documented to interact with this antisense transcript
07

Biomarkers

None established; this RNA is not used in patient selection or monitoring

Beyond the preview

Go deeper on Novel transcript, antisense to NOMO3 (ENSG00000297752).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to NOMO3 (ENSG00000297752).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call